Academic User View: Organ-on-a-Chip Technology
Open accessPublished version of a preprint
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Organ-on-a-Chip (OoC) systems bring together cell biology, engineering, and material science for creating systems that recapitulate the in vivo microenvironment of tissues and organs. The versatility of OoC systems enables in vitro models for studying physiological processes, drug development, and testing in both academia and industry. This paper evaluates current platforms from the academic end-user perspective, elaborating on usability, complexity, and robustness. We surveyed 187 peers in 35 countries and grouped the responses according to preliminary knowledge and the source of the OoC systems that are used. The survey clearly shows that current commercial OoC platforms provide a substantial level of robustness and usability—which is also indicated by an increasing adaptation of the pharmaceutical industry—but a lack of complexity can challenge their use as a predictive platform. Self-made systems, on the other hand, are less robust and standardized but provide the opportunity to develop customized and more complex models, which are often needed for human disease modeling. This perspective serves as a guide for researchers in the OoC field and encourages the development of next-generation OoCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the huge amount of data generated, especially for high-throughput screenings of PDOs, has called for an increasing use of artificial intelligence-driven data analysis algorithms such as machine learning169”
From Human disease models in drug development (2023) · cites this paper as [169]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“these models mainly focus on preclinical safety testing and not disease modelling and are not customizable169”
From Human disease models in drug development (2023) · cites this paper as [169]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“a survey amongst scientists that do not use OoC setups revealed that the lack of ready-to-use-systems and production facilities as well as high entry barriers and costs are the main reasons for not employing OoCs169”
From Human disease models in drug development (2023) · cites this paper as [169]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Xia, Y., & Whitesides, G. M. (1998) · Annual Review of Materials Science · doi:10.1146/annurev.matsci.28.1.153 · Cited by 4,611
Reconstituting organ-level lung functions on a chip
Huh, D., Matthews, B. D., Mammoto, A., Montoya-Zavala, M., Hsin, H. Y., & Ingber, D. E. (2010) · Science · doi:10.1126/science.1188302 · Cited by 4,250
Organs-on-chips: into the next decade
Low, L. A., Mummery, C., Berridge, B. R., Austin, C. P., & Tagle, D. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0079-3 · Cited by 1,029 · cited 1×
“They are on the verge of widespread use as new models for studying diseases and drug response/toxicity in both academia and the pharmaceutical industry [1].”
BackgroundA Human Disease Model of Drug Toxicity–Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice
Huh, D., Leslie, D. C., Matthews, B. D., Fraser, J. P., Jurek, S., Hamilton, G. A., Thorneloe, K. S., McAlexander, M. A., & Ingber, D. E. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004249 · Cited by 993
Organ-on-a-Chip: A New Paradigm for Drug Development
Ma, C., Peng, Y., Li, H., & Chen, W. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.11.009 · Cited by 576
Wagner, I., Materne, E.-M., Brincker, S., Süßbier, U., Frädrich, C., Busek, M., Sonntag, F., Sakharov, D. A., Trushkin, E. V., Tonevitsky, A. G., et al. (2013) · Lab on a Chip · doi:10.1039/c3lc50234a · Cited by 476 · cited 1×
“For drug screening, for instance, organ interactions are often important; therefore, most commercial platforms focus especially on this aspect either by implementing media recirculation to different organ compartments [31] or by using pipetting robots to couple single organ models with each other [32].”
BackgroundSelf-citationRobotic fluidic coupling and interrogation of multiple vascularized organ chips
Novak, R., Ingram, M., Marquez, S., Das, D., Delahanty, A., Herland, A., Maoz, B. M., Jeanty, S. S. F., Somayaji, M. R., Burt, M., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0497-x · Cited by 427 · cited 1×
“For drug screening, for instance, organ interactions are often important; therefore, most commercial platforms focus especially on this aspect either by implementing media recirculation to different organ compartments [31] or by using pipetting robots to couple single organ models with each other [32].”
BackgroundAdaptive regulation of wall shear stress optimizing vascular tree function
Kamiya, A., Bukhari, R., & Togawa, T. (1984) · Bulletin of Mathematical Biology · doi:10.1007/bf02463726 · Cited by 298 · cited 1×
“Mechanical stimulation is important for cell functionality and maturation [18]—most prominently by flow-induced shear stress [33].”
BackgroundTrietsch, S. J., Naumovska, E., Kurek, D., Setyawati, M. C., Vormann, M. K., Wilschut, K. J., Lanz, H. L., Nicolas, A., Ng, C. P., Joore, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00259-3 · Cited by 290 · cited 1×
“The numerous possibilities with OoC customization enable researchers not only to choose the complexity level of the cellular structures (non-3D and 3D) and media perfusion (gravity [6] or external/internal pump [7]) but also to adapt the system to a plethora of readouts (Figure 1).”
Background3D microfluidic liver cultures as a physiological preclinical tool for hepatitis B virus infection
Ortega-Prieto, A. M., Skelton, J. K., Wai, S. N., Large, E., Lussignol, M., Vizcay-Barrena, G., Hughes, D., Fleck, R. A., Thursz, M., Catanese, M. T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02969-8 · Cited by 236
Engineering human islet organoids from iPSCs using an organ-on-chip platform
Tao, T., Wang, Y., Chen, W., Li, Z., Su, W., Guo, Y., Deng, P., & Qin, J. (2019) · Lab on a Chip · doi:10.1039/c8lc01298a · Cited by 198
Impact of organ-on-a-chip technology on pharmaceutical R&D costs
Franzen, N., van Harten, W. H., Retèl, V. P., Loskill, P., van den Eijnden-van Raaij, J., & IJzerman, M. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.06.003 · Cited by 165 · cited 1×
“Therefore, OoC technology is projected to be able to reduce research and development costs in the pharmaceutical industry by 10–26% [9].”
BackgroundQuantitative volumetric Raman imaging of three dimensional cell cultures
Kallepitis, C., Bergholt, M. S., Mazo, M. M., Leonardo, V., Skaalure, S. C., Maynard, S. A., & Stevens, M. M. (2017) · Nature Communications · doi:10.1038/ncomms14843 · Cited by 164 · cited 1×
“The currently most common readout methods are optical, including bright-field microscopy, fluorescence microscopy, and post-fixation confocal microscopy, while Raman confocal microscopy [23] is emerging.”
BackgroundStandardisation needs for organ on chip devices
Piergiovanni, M., Leite, S. B., Corvi, R., & Whelan, M. (2021) · Lab on a Chip · doi:10.1039/d1lc00241d · Cited by 155 · cited 4×
“Accordingly, substantial progress has been achieved in the development of standardized systems suitable for high throughput tests in industrial settings [10,11] and a large number of companies that are developing a d working with OoC systems have em rged.”
BackgroundInfluentialReview on the Vascularization of Organoids and Organoids-on-a-Chip
Zhao, X., Xu, Z., Xiao, L., Shi, T., Xiao, H., Wang, Y., Li, Y., Xue, F., & Zeng, W. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.637048 · Cited by 152
Modeling pulmonary cystic fibrosis in a human lung airway-on-a-chip
Plebani, R., Potla, R., Soong, M., Bai, H., Izadifar, Z., Jiang, A., Travis, R. N., Belgur, C., Dinis, A., Cartwright, M. J., et al. (2022) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2021.10.004 · Cited by 148
An end-user perspective on Organ-on-a-Chip: Assays and usability aspects
Junaid, A., Mashaghi, A., Hankemeier, T., & Vulto, P. (2017) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2017.02.002 · Cited by 123 · cited 1×
“Furthermore, if one considers the literature about end-user perspectives on OoC technology [3,4,29], it becomes clear that most commercial platforms are tailored for pharmaceutical testing.”
BackgroundAdvancement of Sensor Integrated Organ-on-Chip Devices
Clarke, G. A., Hartse, B. X., Asli, A. E. N., Taghavimehr, M., Hashemi, N., Shirsavar, M. A., Montazami, R., Alimoradi, N., Nasirian, V., Ouedraogo, L. J. G., et al. (2021) · Sensors · doi:10.3390/s21041367 · Cited by 115 · cited 1×
“, oxygen, specific metabolites, cell toxicity, barrier permeability, and electrical signals) [24,25].”
BackgroundLatest Trends in Biosensing for Microphysiological Organs-on-a-Chip and Body-on-a-Chip Systems
Kratz, S., Höll, G., Schuller, P., Ertl, P., & Rothbauer, M. (2019) · Biosensors · doi:10.3390/bios9030110 · Cited by 96
Human microphysiological systems for drug development
Roth, A., & 2019, M.-W. B. (2021) · Science · doi:10.1126/science.abc3734 · Cited by 94
Translational Roadmap for the Organs-on-a-Chip Industry toward Broad Adoption
Allwardt, V., Ainscough, A. J., Viswanathan, P., Sherrod, S. D., McLean, J. A., Haddrick, M., & Pensabene, V. (2020) · Bioengineering · doi:10.3390/bioengineering7030112 · Cited by 88
Tan, K., Keegan, P., Rogers, M., Lu, M., Gosset, J. R., Charest, J., & Bale, S. S. (2019) · Lab on a Chip · doi:10.1039/c8lc01262h · Cited by 76
Kolanowski, T. J., Busek, M., Schubert, M., Dmitrieva, A., Binnewerg, B., Pöche, J., Fisher, K., Schmieder, F., Grünzner, S., Hansen, S., et al. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.11.044 · Cited by 71 · cited 1×
“Mechanical stimulation is important for cell functionality and maturation [18]—most prominently by flow-induced shear stress [33].”
BackgroundSelf-citation3D Immunocompetent Organ‐on‐a‐Chip Models
Maharjan, S., Cecen, B., & Zhang, Y. S. (2020) · Small Methods · doi:10.1002/smtd.202000235 · Cited by 62 · cited 1×
“Finally, immune-competent chips are an emerging topic [34], often requiring highly specialized OoC designs.”
BackgroundAdoption of organ-on-chip platforms by the pharmaceutical industry
Vulto, P., & Joore, J. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00323-0 · Cited by 58 · cited 3×
“Nevertheless, recently OoCs reached a stage of maturity to influence internal decision making in pharmaceutical companies during drug discovery/testing studies [4].”
BackgroundBusek, M., Nøvik, S., Aizenshtadt, A., Amirola-Martinez, M., Combriat, T., Grünzner, S., & Krauss, S. (2021) · Biosensors · doi:10.3390/bios11050162 · Cited by 41
Self-citationMencattini, A., Mattei, F., Schiavoni, G., Gerardino, A., Businaro, L., Natale, C. D., & Martinelli, E. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00100 · Cited by 40
Putting Science into Standards workshop on standards for organ-on-chip
Piergiovanni, M., Cangar, O., Leite, S. B., Mian, L., Jenet, A., Corvi, R., Whelan, M., Taucer, F., & Ganesh, A. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.07.010 · Cited by 34 · cited 4×
“However, except for a few cases of well-established assays (blood vessel, gut, liver, and lung models) from first-generation companies (CNBio, Mimetas, Emulate, TissUse), OoCs are still not broadly adopted and are far from being able to replace or even reduce animal models [10].”
BackgroundInfluential
Cited by
Human disease models in drug development
Loewa, A., Feng, J. J., & Hedtrich, S. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00063-3 · Cited by 331
Tolabi, H., Davari, N., Khajehmohammadi, M., Malektaj, H., Nazemi, K., Vahedi, S., Ghalandari, B., Reis, R. L., Ghorbani, F., & Oliveira, J. M. (2023) · Advanced Materials · doi:10.1002/adma.202208852 · Cited by 160
Yao, Q., Cheng, S., Pan, Q., Yu, J., Cao, G., Li, L., & Cao, H. (2024) · MedComm · doi:10.1002/mco2.735 · Cited by 122
Sunildutt, N., Parihar, P., Salih, A. R. C., Lee, S. H., & Choi, K. H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1139229 · Cited by 71
“It is driven by the requirement for affordable, trustworthy in vitro models that could replace animals during the most labor-intensive and costly phases of the development of products (Busek et al., 2022).”
BackgroundPump-less, recirculating organ-on-a-chip (rOoC) platform
Busek, M., Aizenshtadt, A., Koch, T., Frank, A. K., Delon, L., Martinez, M. A., Golovin, A., Dumas, C., Stokowiec, J., Grünzner, S., et al. (2022) · Lab on a Chip · doi:10.1039/d2lc00919f · Cited by 58
Self-citation
Metadata
- Authors
- Busek, M., Aizenshtadt, A., Amirola-Martinez, M., Delon, L., & Krauss, S.
- Affiliations
- Oslo University Hospital (NO)
- University of Oslo (NO)
- Hybrid Technology Hub—Centre of Excellence, Institute of Basic Medical Sciences, University of Oslo, 0317 Oslo, Norway
- Corresponding author
- Busek, Mathias
- Venue
- Biosensors
- Publisher
- MDPI AG
- Published
- 2022-02-16
- Volume
- 12
- Issue
- 2
- Pages
- 126
- ISSN
- 2079-6374 (ISSN-L)
- PMC
- PMC8869899
- OpenAlex
- W4213098544
- Cited by
- 37
- References
- 28
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 10 · 2023: 10 · 2022: 5
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biosensors (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- NORA - Norwegian Open Research Archives (submittedVersion, cc-by)
- Funders
- European Union (Marie Skłodowska-Curie Actions Grant agreement No 801133)
- The Research Council of Norway (Centers of Excellence scheme, project number 262613)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
- Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
- Keywords
- organ-on-a-chip, in vitro model, usability, robustness, complexity, drug development, human disease modeling, prediction model, user survey
- MeSH terms
- Drug Development, Humans, Technology, Lab-On-A-Chip Devices
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.